Factors influencing Ki67 calculation in neuroendocrine neoplasia

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2017-03-23 DOI:10.2217/IJE-2016-0011

C. Castañeda, Miluska Castillo, Juvenal Sanchez, S. Casavilca, C. Gonzalez, C. Flores, Luis Cano, Carolina Belmar-López, Rosario Villa-Robles, Gabriela Rios-Martini, Yun Wu

引用次数: 0

Abstract

Aim: We compared different methodologies to evaluate Ki67 in neuroendocrine neoplasia (NEN). Patients & methods: ki67 was evaluated using three methods in 70 NEN cases: manual-count, eyeballed estimate made by three pathologists and ImmunoRatio-software. Manual-count was the standard method and agreement with it was evaluated through intraclass correlation (ICC). Results: Agreement between manual-count and eyeballed estimate had ICC: 0.887–0.929. Eyeballed estimate by three pathologists produced upgradation in 5.7–32.9% and downgradation in 5.7% of NEN cases. Agreement for ImmunoRatio-count had ICC: 0.989. Immunoratio produced upgradation in 17.1% and downgradation in 8.5% cases. Agreement between all methods was higher at low-Ki67. Cellularity, immune-cell infiltration, staining and sample quality did not affect agreement. Conclusion: Eyeballed estimate and ImmunoRatio showed good accuracy, especially at low-Ki67.

查看原文本刊更多论文

影响神经内分泌肿瘤Ki67计算的因素

目的:比较不同方法对神经内分泌瘤(NEN) Ki67的评价。患者与方法:对70例NEN病例采用三种方法对ki67进行评估:手工计数、三名病理学家的目测和ImmunoRatio-software。手工计数为标准方法，并通过类内相关性(ICC)评价其一致性。结果:手工计数与目测的一致性ICC: 0.887-0.929。三名病理学家的肉眼估计导致5.7-32.9%的NEN病例升级，5.7%的NEN病例降级。免疫协议计数ICC: 0.989。免疫接种导致17.1%的患者升级，8.5%的患者降级。在低ki67时，所有方法之间的一致性更高。细胞结构、免疫细胞浸润、染色和样品质量不影响一致性。结论:肉眼估计和免疫比具有良好的准确性，特别是在低ki67时。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.